Compare Cassava Sciences Inc (FLNA) vs iShares Core High Dividend ETF (HDV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs iShares Core High Dividend ETF — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while iShares Core High Dividend ETF trades at $28.21. The key difference: iShares Core High Dividend ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | HDV | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | — |
52-Week High | $4.64 | $28.09 |
52-Week Low | $1.09 | $23.64 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
HDV, the iShares Core High Dividend ETF, trades at $28.20, up 2.03% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. Recent corporate actions include a 1:5 stock split in April 2026 and upcoming dividend payments. The ETF focuses on large-cap value stocks with a defensive tilt, emphasizing high-quality, dividend-paying companies. News coverage highlights its competitive expense ratio and comparisons with peers like SCHD and VYM.
The outlook for HDV is supported by its defensive sector allocation and income focus, appealing in uncertain markets. Risks include concentration in energy and healthcare, which may introduce volatility. Analyst sentiment is mixed, weighing yield against diversification. The ETF suits investors seeking steady dividends with moderate growth, but sector-specific risks require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →
